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Abstract
Adaptor proteins (AP 1–5) are heterotetrameric complexes that facilitate specialized cargo sorting in vesicular-mediated
trafﬁcking. Mutations in AP5Z1, encoding a subunit of the AP-5 complex, have been reported to cause hereditary spastic
paraplegia (HSP), although their impact at the cellular level has not been assessed. Here we characterize three independent
ﬁbroblast lines derived from skin biopsies of patients harbouring nonsense mutations in AP5Z1 and presenting with spastic
paraplegia accompanied by neuropathy, parkinsonism and/or cognitive impairment. In all three patient-derived lines, we show
that there is complete loss of AP-5 ζ protein and a reduction in the associated AP-5 µ5 protein. Using ultrastructural analysis, we
show that these patient-derived lines consistently exhibit abundant multilamellar structures that are positive for markers of
endolysosomes and are ﬁlled with aberrant storagematerial organized as exaggeratedmultilamellar whorls, striated belts and
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‘ﬁngerprint bodies’. This phenotype can be replicated in a HeLa cell culture model by siRNA knockdown of AP-5 ζ. The cellular
phenotype bears striking resemblance to features described in a number of lysosomal storage diseases (LSDs). Collectively,
these ﬁndings reveal an emerging picture of the role of AP-5 in endosomal and lysosomal homeostasis, illuminates a potential
pathomechanism that is relevant to the role of AP-5 in neurons and expands the understanding of recessiveHSPs.Moreover, the
resulting accumulation of storagematerial in endolysosomes leads us to propose that AP-5 deﬁciency represents a new type of
LSDs.
Introduction
Adaptor proteins (AP 1–5) are ubiquitously expressed protein
complexes that facilitate vesicle-mediated intracellular sorting
and trafﬁcking of selected transmembrane cargo proteins (1).
To date, mutations in components of all ﬁve AP complexes
have been reported to impact human health [for which the
term ‘adaptinopathies’ has been proposed (2)]. AP-5, similar to
the other APs, comprises a core of four proteins, namely, ζ, β5,
µ5 and σ5 subunits, which share structural similarity to corre-
sponding subunits in other AP complexes. AP-5 is the most re-
cently identiﬁed member of this protein family, and little is
known about the cellular pathway(s) that AP-5 may play a role
in, nor what the cargo speciﬁcity of AP-5 might be. However,
some important clues are emerging from the integration of pro-
teomics, cell biology and clinical genetics.
AP-5 has been shown to associate in a stable complex with
two other proteins, spatacsin (SPG11) and spastizin [SPG15;
FYVE-CENT; ZFYVE26 (3,4)], and to co-localize with markers of
endosomes and lysosomes (4,5), suggesting a role of AP-5 along
with spatacsin and spastizin in the endosomal pathway. Intri-
guingly, loss-of-function mutations in SPG11 (6–9), ZFYVE26
(SPG15) (10,11) and AP5Z1 [SPG48 (3,12–14)] have all been de-
scribed in patients with hereditary spastic paraplegia (HSP).
HSPs are a group of neurological disorders typiﬁed by the degen-
eration of the long corticospinal axons leading to progressive
lower limbmuscleweakness and spasticity and further classiﬁed
into pure or complex forms on the basis of additional neurologic-
al signs (15,16). Mutations in SPG11 and SPG15 generally result in
a complex form of HSP, which is distinguished by prominent
thinning of the corpus callosum, but also includes other neuro-
logical complications such as retinal abnormalities, intellectual
disability, mild ataxia and parkinsonism (11,17). SPG48 patients
have some clinical features similar to those of SPG11 or SPG15 pa-
tients, including spastic paraplegia, retinal abnormalities and
parkinsonism, but the clinical spectrum of AP5Z1 patients is
still being deﬁned.
In this study, we investigate ﬁbroblast lines from three pa-
tients harbouring distinctmutations inAP5Z1, which offers a un-
ique framework to investigate where and how AP-5 may be
functioning. We show that mutations in AP5Z1 impair AP-5 com-
plex formation and result in the accumulation of multilamellar
structures containing aberrant storage material, revealing lyso-
somal dysfunction as the likely pathogenic mechanism.
Results
Effects of AP5Z1 mutations on AP-5 protein abundance
and localization
AP-5 (Fig. 1A), similar to other AP complexes, is expressed in
many tissues, including various regions of the brain and spinal
cord, and at all stages of development (Supplementary Material,
Fig. S1). This widespread expression pattern makes the use of
ﬁbroblasts derived from skin biopsies a relevant model system
for the investigation of the cellular impact of mutations in AP5Z1.
We analysed AP-5 protein levels in three SPG48 patient-derived
ﬁbroblast lines with mutations in AP5Z1 : (i) c.1732C>T (p.Q578*),
(ii) c.[412C>T];[1322G>A] (p.[R138*];[W441*]) and (iii) c.[80_83del4;
79_84ins22] (p.R27Lfs*3) (Fig. 1B), along with gender-matched and
age-matched controls. The levels of AP-5 ζ protein correlated well
with the predicted nature of themutations, and AP-5 ζ proteinwas
decreased to undetectable levels (Fig. 1C). In addition, there was a
concomitant reduction in levels of µ5 compared with controls,
which is due to protein instability of AP subunits that occurs in
the absence of complex assembly (18–20). These results suggest
that in these patient lines there is a loss of functional AP-5 and
supports the obligate nature of AP complexes.
Phenotypic effects of loss of AP-5
In control ﬁbroblasts, AP-5 ζ localized in ﬁne puncta throughout
the cytoplasm and co-localized with LAMP1, a marker of late en-
dosomes and lysosomes (Fig. 2A, control lines). This is consistent
with our previous localizations of AP-5 (4,21). In contrast, the AP-
5 ζ punctate labelling was lost in all patient lines [note that the
Golgi pattern seen here is due to a cross-reacting activity also
noted in (4)]. The loss of AP-5 ζ correlated with the consistent ap-
pearance of larger LAMP1-positive puncta. Using automated mi-
croscopy, we could quantify an increase in the area of LAMP1
ﬂuorescence (Fig. 2B and C), although this had no signiﬁcant ef-
fect on total LAMP1 protein levels (Fig. 2D).
Each patient-derived cell line was then assessed for morpho-
logical changes by electronmicroscopy (EM). Consistent with the
immunoﬂuorescence data, we observed large multilamellar
structures surrounded by a single bilayer membrane (Fig. 3A
and Supplementary Material, Fig. S2). Thesemultilamellar struc-
tures had morphological features of hybrid organelles (derived
from the fusion of endosomes and lysosomes), but were ﬁlled
with aberrant storage material typiﬁed by multiple exaggerated
whorls, belts of striations, ﬁngerprint bodies and some intralum-
inal vesicles. Quantiﬁcation of all morphologically deﬁned endo-
cytic structures showed that although the average overall sizes of
endocytic structures had not changed signiﬁcantly (Fig. 3B), there
was a dramatic increase in the number of structures with fea-
tures consistent with hybrid organelles (Fig. 3C and Supplemen-
tary Material, Fig. S2). It was also noted that there was a striking
clustering of these multilamellar structures (Fig. 3D), and this
likely accounts for the larger appearance of the LAMP1 immuno-
labelling in AP-5-deﬁcient ﬁbroblasts (Fig. 2A) and the increase in
the area of LAMP1 puncta quantiﬁed for the p.Q578* line on the
automated microscope (Fig. 2C). Generally, by EM, the control ﬁ-
broblasts containedmorphologically ‘normal’ endosomes and ly-
sosomes, and only occasionally contained some storagematerial
that appeared as a belt of striations or as a singlewhorl, butmuch
less exaggerated in appearance and far less common than in pa-
tient ﬁbroblasts (Fig. 3D and Supplementary Material, Fig. S2).
In HeLa cells knocked down using siRNA against AP-5 ζ, we
could recapitulate the appearance of larger LAMP1 puncta
(Fig. 4A) and could conﬁrm this using an alternative marker of
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late endocytic and lysosomal structures, CD63 (Supplementary
Material, Fig. S3). We could quantify an increase in brightness
and area of LAMP1 labelling on an automated microscope
(Fig. 4B and C), which was reﬂected in an increase in the overall
levels of LAMP1 (Fig. 4D). In general, these effectsweremore strik-
ing than those in the patient ﬁbroblasts (Fig. 2C), which could be
explained by the heterogeneity in the size and shape of patient
ﬁbroblasts that makes quantiﬁcation of differences harder to
measure and/or reﬂects the difference in acute versus chronic
knockdown (i.e. patient cells may have had time to engage com-
pensatory mechanisms). Consistent with the patient ﬁbroblast
EM data, ultrastructural analysis revealed the accumulation of
multilamellar structures with morphological features of hybrid
organelles, along with an array of aberrant storage materials
(compare Fig. 4E with F).
Collectively, these observations indicate that the accumulation
of enlarged late endolysosomal structures containing aberrant
storage material is due to the loss of AP-5. Furthermore, the accu-
mulation of aberrant storage material is reminiscent of features
described in many lysosomal storage diseases (LSDs) and is indi-
cative of dysfunction along the endosomal/lysosomal pathway.
Relationship between spatacsin/spastizin and AP-5
Although spatacsin and spastizin have been shown to associate
with AP-5 (3,4), there are conﬂicting reports about the function
of spastizin (3,22–24), as well as the obligate nature of their
association (5,25). Here we qualify their relationship and show
that depletion of spastizin using siRNA in HeLa cells leads to re-
duction of the protein levels of both AP-5 ζ and µ5 (Fig. 5A). We
also ﬁnd that there is a consequent accumulation of aberrant
LAMP1-positive structures (Supplementary Material, Fig. S4),
reminiscent of what has been previously reported in the SPG15
knockoutmouse (5), patient ﬁbroblasts (26) and HeLa knockdown
cells (25). Consistent with these observations, we also ﬁnd a re-
duction in the AP-5 ζ protein levels in SPG11 and SPG15 patient
ﬁbroblasts (Fig. 5B). The reciprocal relationship, however, does
not appear to be the same, with depletion of AP-5 ζ not altering
the total level of spastizin (Fig. 5A) or the membrane association
of spatacsin (Fig. 5C). Taken together, we ﬁnd that although AP-5
is dependent on spastizin and spatacsin, it is possible that spa-
tacsin and spastizin can function independently of AP-5.
Loss of AP-5 mutations leads to accumulation of
endolysosomes
The maintenance of endosomal and lysosomal homeostasis is
complex, and progress through the endocytic pathway involves
homotypic fusion between endosomes as well as heterotypic fu-
sion between endosomes and lysosomes (27,28). Endolysosomes
are deﬁned as hybrid or intermediate compartments that appear
transiently, following the fusion of endosome and lysosome
[prior to reformation of lysosomes (28–30)], and arehydrolytically
active (29).
Figure 1. Effect of AP5Z1 mutations on AP-5 protein expression. (A) Schematic diagram of AP-5 subunit organization. (B) Table detailing nonsense mutations in AP5Z1
described in this study, in which premature terminations are indicated by asterisk. (C) Whole-cell western blots of patient-derived ﬁbroblast lines including gender-
and age-matched controls, loaded at equal protein levels and probed with antibodies against AP-5 ζ, AP-5 µ5 and clathrin (CHC; loading control). Note the loss of AP-5
ζ and concomitant reduction in levels of µ5.
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Figure 2. Loss of AP-5 in patient-derived ﬁbroblasts. (A) Immunoﬂuorescence of patient-derived ﬁbroblasts (denoted by their mutation) and their respective gender- and
age-matched controls doubled-labelled with antibodies against AP-5 ζ and LAMP1. Note that in control cells there is a signiﬁcant overlap between LAMP1 and AP-5 ζ. In
AP5Z1 patient lines, there is loss of the punctate AP-5 labelling pattern [the antibody cross-reacts with a reticular Golgi protein (white arrowhead), and this
immunoreactivity persists when cells are depleted of AP-5 ζ by siRNA knockdown (4)]. Note that with the loss of AP-5 ζ, there is a consistent increase in the brightness
and size of the LAMP1-positive puncta. Scale bar = 20 µm. (B) Patient-derived ﬁbroblasts (p.Q578*) and their control (control_1) were plated onto 96-well plates and labelled
with a whole-cell stain (WCS) and an antibody against LAMP1; the WCS allowed a mask to be drawn around the cells (pink) and various parameters of LAMP1 puncta
(green) to be quantiﬁed on an ArrayScan Cellomics microscope using a SpotDetector algorithm. Scale bar = 20 µm (C) Spot average intensity and average area per
object were quantiﬁed in three independent experiments, with more than 1000 cells quantiﬁed per experiment. Note that there is a subtle but signiﬁcant increase in
the area of the LAMP1-positive puncta. (D) Western blots of patient-derived ﬁbroblasts probed for LAMP1, AP-5 ζ and clathrin (CHC; loading control). Note that there is
no apparent increase in the total levels of LAMP1 protein.
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In order to investigate further the nature of the enlarged
multilamellar structures in the AP-5 patient lines, we used cryo-
immunoelectron microscopy and acidotropic and hydrolytic-
activity-dependent ﬂuorescent probes. Correlating with the
immunoﬂuorescence, we observed enlarged multilamellar struc-
tures positive for LAMP1, CD63 and lysobisphosphatidic acid
(LBPA) (Fig. 6A). Speciﬁcally, LAMP1 was restricted to the limiting
membrane rather than internal membranes, whereas CD63 and
Figure 3. Ultrastructure of AP5Z1 p.Q578* ﬁbroblasts. (A) EM of patient-derived ﬁbroblasts. Note the accumulation of morphologically deﬁned endocytic structures ﬁlled
with aberrant storage material typiﬁed bymultiple exaggeratedmembrane whorls (ﬁlled arrow head), belts of striated material (double arrow), ﬁngerprint bodies (arrow)
and some intraluminal vesicles (open arrow head). These structures are predominantly surrounded by a single bilayer membrane, and there is clustering of endocytic
structures marked by arrowheads with white outline (far left panel; EL, endolysosome). Scale bar = 500 nm. (B) Images were collected from 10 cells and the size of
endocytic structures measured (96 for control_1 and 191 for the p.Q578* line); the individual data are shown for endolysosomes (Endolyso), endosomes (Endo) and
lysosomes (Lyso) and combined together to show all endocytic structures. Note that no signiﬁcant difference in the overall size of endocytic structures was revealed.
(C) The number of different endocytic structures per unit area of cytoplasm was measured. Images were collected from 10 cells and the number of endocytic
structures measured (96 for control_1 and 191 for the p.Q578* line). Note the increase in the number of endolysosomes per unit area of cytoplasm in the p.Q578* line.
(D) Examples of AP5Z1 p.Q578* ﬁbroblasts showing the clustering of endolysosomes compared with its control. Scale bar = 1 µm.
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Figure 4. Loss of AP-5 by siRNA knockdown in HeLa cells. (A) Immunoﬂuorescence of HeLa cells treated with siRNA targeting AP-5 ζ or non-targeting control labelled with
an antibody against LAMP1. Note that the depletion of AP-5 ζ results in brighter and larger LAMP1 puncta. Scale bar = 20 µm. (B) HeLa cells treated with an siRNA targeting
AP-5 ζ or non-targeting control were plated onto 96-well plates and labelled with awhole-cell stain (WCS) and an antibody against LAMP1; theWCS allowed a mask to be
drawn around the cells (pink) and various parameters of LAMP1 labelling (green) to be quantiﬁed on an ArrayScan Cellomics microscope using a SpotDetector algorithm.
Scale bar = 20 µm. (C) Spot average intensity and average area per object were quantiﬁed in three independent experiments, with more than 1000 cells quantiﬁed per
experiment. Note the signiﬁcant increase in the area of LAMP1-positive puncta. (D) Western blots of HeLa cells treated with an siRNA targeting AP-5 ζ or non-targeting
control were loaded at equal protein and probed with antibodies against LAMP1, AP-5 ζ and clathrin (CHC; used as a loading control). Note that there is an increase in the
total level of LAMP1. (E) EMwas performed onHeLacells treatedwith siRNA targetingAP-5 ζ (E) or a non-targeting control (F). Scale bar = 500 nm.Note that the loss of AP-5 ζ
led to the accumulation of enlarged morphologically deﬁned endosomal structures ﬁlled with aberrant storage material, typically containing bands of striated material,
multiple exaggerated membrane whorls and many intraluminal vesicles.
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LBPA, which are enriched on intraluminal vesicles (31,32), were
principally associated with intraluminal whorls and striations.
We also labelled live cells with Lysotracker Red, a ﬂuorescent
dye for labelling and tracking acidic organelles in live cells, and
Magic Red Cathepsin B substrate, which is used to assess cathe-
psin activity (31), and could show that these enlarged structures
were acidic as well as hydrolytically active (Fig. 6B and C).
In HeLa cells depleted of AP-5 ζ, not only did we observe accu-
mulation of aberrantmultilamellar structures, but also clustering
of morphologically deﬁned early endosomes (Fig. 7A), which by
immunoﬂuorescence labelled positive for CIMPR and distinct
from the LAMP1 labelling (Fig. 7B). This is reminiscent of the
phenotype that we reported following the knockdown of any
one of the subunits of AP-5, although in our previous study we
did not look at the impact of loss of AP-5 on LAMP1 (21). We
could not do equivalent experiments in ﬁbroblast lines as at stea-
dy state CIMPR is mainly localized to the trans-Golgi network
(Supplementary Material, Fig. S5).
As AP-5 is known to associatewith spastizin, which has been
reported to play a role in either autophagosome–lysosome fu-
sion (23) or recovery of lysosomes from autolysosomes (25), we
felt it pertinent to determine whether these enlarged multila-
mellar structures were positive for LC3, a marker of autophago-
somes. Under basal conditions, we found that these enlarged
LAMP1-positive structures did not label for LC3 in either HeLa
knockdowns (Supplementary Material, Fig. S6A) or patient
ﬁbroblasts (Supplementary Material, Fig. S6B), although there
appears to be very little basal autophagy in these cells. This ﬁnd-
ing led us to believe that these structures were unlikely to be
autophagosomes.
Figure 5.AP-5 is dependent on spatacsin and spastizin. (A) Western blots of HeLa cells were treatedwith siRNA against spastizin or non-targeting control and probedwith
antibodies against spastizin, AP-5 ζ and clathrin (CHC; used as a loading control). Note that there is loss of AP-5 ζ and µ5 when spastizin is depleted. (B) Western blots of
patient ﬁbroblastswithmutations inAP5Z1 (Patient 3: p.R27Lfs*3), SPG11 or SPG15were probedwith antibodies against AP-5 ζ and tubulin (used as a loading control). Note
that there is loss of AP-5 ζ in SPG11 and SPG15 patient ﬁbroblasts. (C) Immunoﬂuorescence of patient-derived ﬁbroblast cells and controls were labelled with antibodies
against spatacsin. Note that in patient cells lacking AP-5 ζ, there is no signiﬁcant loss ofmembrane-associated spatacsin, and the puncta appear larger. Scale bar = 20 µm.
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Collectively, these observations deﬁne these enlarged aber-
rant structures as having characteristics of endolysosomes and
as such are likely to be the product of the fusion of late endo-
somes with lysosomes. Furthermore, the accumulation of these
structures results in the clustering of early endosomes, which
suggests that there is a disruption of endosomal and probably
lysosomal dynamics/homeostasis.
Discussion
Here we present the description of three patient-derived ﬁbro-
blast lines with mutations in AP5Z1. Although two mutations
have been reported previously (3,12), the impact of these muta-
tions on AP-5 and at the cellular level had not been determined.
All the patients presented with spastic paraplegia that was ac-
companied by neuropathy, parkinsonism and/or cognitive im-
pairment (3,12). At the cellular level, these lines show loss of
AP-5 ζ protein alongwith a reduction in levels of AP-5 µ5, consist-
ent with these proteins existing as an obligate complex (4). Ultra-
structural analysis of patient-derived lines and HeLa cells
depleted of AP-5 ζ demonstrate that the loss of AP-5 results in
an accumulation of enlarged multilamellar structures that are
ﬁlled with aberrant storage material. Age does not appear to be
a signiﬁcant contributor to this phenotype as these features
were not observed in age-matched controls, nor is there a strong
correlation with severity and age.
AP-5 ζ and spastizin have been shown to associate in a stable
complex, alongwith coremembers of AP-5 (β5, µ5 and σ5) and spa-
tacsin (3,4). In agreementwith this observation, the subclinical loss
of function of both spatacsin and spastizinwasassociatedwith ab-
normal motoneuron development in zebraﬁsh (33). This provided
amolecular explanation for the close similarity in the clinical pres-
entation of SPG11 or SPG15 (17) and their overlap with SPG48 pa-
tient features (3,12,13). What can the cell biology characterization
tell us about the relationship between AP-5 and spatacsin/spasti-
zin? Here we show that abrogation of spatacsin and spastizin re-
sults in the decrease of AP-5, similar to results in SPG11 or SPG15
patient-derived ﬁbroblasts (25) and HeLa knockdown studies (4).
Collectively, these observations suggest that AP-5 is dependent
on spatacsin and spastizin foreither its assemblyor its recruitment
Figure 6. Identiﬁcation of endolysosomes in AP-5 patient lines. (A) Cryo-immunoelectron microscopy of patient-derived ﬁbroblasts (p.Q578*) labelled with antibodies
against the late endosomal/lysosomal markers, LAMP1, LBPA and CD63. Note that the enlarged endocytic structures label positive for all markers, with LAMP1
labelling restricted to the limiting membrane, and LBPA and CD63 largely restricted to intraluminal whorls and striations. Scale bar = 200 nm. (B) Live imaging of
control and patient-derived ﬁbroblasts following incubation with Magic Red Cathepsin B reagent for 45 min at 37°C. Note that the enlarged structures in the patient
lines are positive for cathepsin B activity and are therefore hydrolytically active. Scale bar = 20 µm. (C) Live imaging of control and patient-derived ﬁbroblasts
incubated with Lysotracker Red at 37°C. Note that the enlarged structures in the patient lines are positive for Lysotracker Red and are therefore acidic. Scale bar = 20 µm.
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to membranes, but the converse is not true as spatacsin and
spastizin are still recruited to membrane in the absence of AP-5
(see also 4,25). The fact that spatacsin and spastizin may be
able to function in the absence of AP-5 may help explain
alternative functions attributed to SPG15, such as in dense core
granule formation (22), or its role in autophagosome fusion (23).
What is the nature of the aberrant multilamellar structures
found in patients with mutations in AP5Z1? We ﬁnd that they
Figure 7. Loss of AP-5 results in the clustering of early endosomes. (A) EM of HeLa cells knocked down for AP-5 ζ. Note the clustering of morphologically deﬁned early
endosomes (typiﬁed by being electron-lucent with few intraluminal vesicles), surrounded by many small vesicles that we believe to be tubules in cross-section.
Adjacent to this cluster of early endosomes is an example of an endolysosome ﬁlled with aberrant storage material. Scale bar = 500 nm. (B) Immunoﬂuorescence of
HeLa cells treated with siRNA against AP-5 ζ or a non-targeting control and double-labelled with antibodies against CIMPR and LAMP1. Note that the depletion of AP-5
ζ resulted in the clustering of CIMPR labelling that does not overlap signiﬁcantly with LAMP1. Scale bar = 20 µm.
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label for LAMP1 at the limiting membrane, and CD63 and LBPA
are largely restricted to intraluminal membrane whorls; they
are acidic and hydrolytically active, are not positive for the autop-
hagy marker LC3 and are surrounded by a single bilayer mem-
brane. In the context of current models, these features are
consistent with endolysosomes, and we would suggest that the
storagematerial results from the partial degradation of intralum-
inal vesicles that are CD63- and LBPA-positive (31,32). Notably,
similar ultrastructural features have been described for several
LSDs including metachromatic leukodystrophy, Fabry disease,
mucopolysaccharidoses, Niemann–Pick disease, GM2 gangliosi-
doses, I-cell disease [where EM features have been reported as
lamellar lipids and ‘zebra bodies’ (34)], mucolipidosis (‘concentric
multilaminar membrane structures’ (35)] and neuronal ceroid
lipofuscinosis [‘ﬁngerprint bodies’ (36,37)].
Does AP-5 deﬁciency deﬁne a new type of LSD? Although LSDs
were ﬁrst classiﬁed on the basis of lysosomal enzyme deﬁciency
that leads to inability to metabolize lipids, glycoproteins or glyco-
saminoglycans, there are nowmany LSDs that include deﬁciencies
in lysosomal transmembrane proteins, soluble non-enzymatic
lysosomal proteins and proteins important for trafﬁcking to or
from lysosomes (34,38–40). The broader deﬁnition of LSDs there-
fore encompasses defects in the lysosomal structure and function
(41) that, for less well-deﬁned reasons, result in the accumulation
of undegradable material in the endosomal/lysosomal system.
Two classes of LSDs have been proposed: primary LSDs that arise
from defects in speciﬁc lysosomal enzymes and secondary LSDs
that result from impaired membrane trafﬁc (42). Therefore, al-
though at this point it is not clear what causes the accumulation
of storage material in AP-5-deﬁcient ﬁbroblasts, it seems likely to
be a secondary LSD, and the exaggerated membrane whorls
could point to a deﬁcit in the ability tometabolize lipids (34). Inter-
estingly, the clinical features of neuropathic LSDs are similar to
those described in SPG48 patients (3,12,13), as well as SPG11 and
SPG15, including cognitive impairment, ataxia, peripheral neur-
opathy, parkinsonism and spasticity (42). Clinically, it can be chal-
lenging to distinguish classical LSDs and some forms of complex
HSP, as evidenced by reports of patients originally suspected to
have HSP but subsequently diagnosed with LSD [e.g. Krabbe’s dis-
ease (43) and ceroid lipofuscinosis (14)].
Formany LSDs, it has been reported that the progressive accu-
mulation of storage material leads to the build-up of enlarged
(>1 µm) lysosomes that are dysfunctional (44). The parallels be-
tween loss of AP-5 and LSDs allow us to hypothesize a simple
model for the pathogenesis of AP-5 deﬁciency related to lyso-
somal dysfunction. Here, we ﬁnd that AP-5 is expressed in neu-
rons of the cortex, hippocampus and cerebellum, as well as in
non-neuronal tissues. Neurons are known to be particularly sen-
sitive to aberrant lysosomal storage or dysfunction. The ques-
tions of what the increase in endolysosome frequency means,
why aberrant storage material accumulates, how this impacts
neuron survival and what this means for the role of AP-5 are
complex. The increase in endolysosome frequency may arise
by a number of scenarios that are not mutually exclusive.
These include increased endosome and lysosome fusion events,
increased biosynthetic delivery [for example, by LAMP carriers
(45)], decreased degradation of content or decreased lysosomal
recovery. In addition, the accumulation of endolysosomes will
likely impact upon upstream and downstream endosomal and
lysosomal functions, as well as other organelle functions (42). In-
deed, we have seen that in HeLa cells depleted of AP-5 ζ, CIMPR
accumulates in early endosomes, which may underlie a more
general perturbation of membrane trafﬁcking, and could be due
to the displacement of fusion machinery (e.g. SNAREs).
In the context of current models, our data are consistent with
the loss of AP-5 disturbing the equilibrium between endosomes,
endolysosomes and lysosomes. We favour a model whereby AP-5
could act in the recovery of lysosomes from endolysosomes
because of its association with spatacsin and spastizin and the
mechanistic similarities with lysosome reformation from autoly-
sosomes (25). This is in keeping with the role of other LSD proteins
including TRPML1 [mucolipidosis type IV (46)] and NPC2 [Nie-
mann–Pick type C (47)] that are involved in the regulation of lyso-
some formation. Given the role of AP complexes in protein
sorting, it seems plausible that the main role of AP-5 may be
in the selection of cargos to/from these organelles, the loss of
which impacts upon endosome/lysosome homeostasis. One of
the challenges for the future will be to identify possible AP-5
cargo proteins (as well as accessory proteins) through the use of
technologies such as CRISPR knockout and acute ablation techni-
ques. This may help deﬁne not only the role of AP-5 in normal
cell physiology but may clarify how loss of function of AP-5 may
lead lysosomal dysfunction and to disease. This in turn may be
relevant to other HSPs (particularly SPG11 and SPG15) and LSDs
and expand our understanding of recessive HSPs. Furthermore, it
will be interesting to determine whether there are mutations in
the other subunits of AP-5 and to determine the full spectrum of
clinical features. Although the number of HSP patients withmuta-
tions inAP5Z1 is still low, their description reafﬁrms the important
roles of all ﬁve AP complexes, which is encompassed by the broad
deﬁnition of ‘adaptinopathy’ that was coined to deﬁne this class of
disorders of intracellular trafﬁcking (2).
Materials and Methods
Patients and patient-derived ﬁbroblasts
Patient p.Q578* is a man in his early 70s (age of symptom onset
about 60) with neuropathy, spastic paraplegia, ataxia, retinop-
athy and parkinsonism. Patient p.[R138*];[W441*] is a woman in
her 50s (age of onset late 40s), with a complex form of HSP with
cognitive decline (12). Patient p.R27Lfs*3 is a woman in her 80s
who initially presented with urinary incontinence at 49 years of
age, which progressed to spastic paraplegia and neuropathy (3).
Fibroblastswere established fromskin punch biopsies from these
patients alongwith gender- and age-matched controls, under ap-
proved clinical protocols (NINDS Institutional Review Board,
protocol 2000-N-0043), with subjects’ informed consent obtained.
Following establishment of patient lines and controls, all patient
and control cells were cultured side-by-side, and experiments
were performed on equivalent passage number (all less than 10
passages) in order to reduce operator differences and differences
due to time in culture.
For comparison, we also used ﬁbroblasts from two SPG11 and
two SPG15 patients with symptoms typical of these pathologies.
One SPG15 patient of Portuguese origin carries the homozygous
c.6296dup (p.N2100Efs*12) mutation (48) and another from Syria
carries the homozygous c.5036delT (p.L1679Rfs*1687) mutation
(10). One SPG11 patient from Morocco carries the homozygous
c.6100C>T (p.Arg2034*) nonsense variant (6), and the second
SPG11 case originated from Latvia and has a heterozygous
c.2431C>T (p.Q811*) variant in trans of a deletion affecting exon
29 (A.D. and G.S., unpublished data).
Antibodies
Antibodies used in this study include in-house antibodies
against clathrin, AP-5 ζ (monoclonal antibody used for IF), µ5
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and SPG11 monoclonal (4) and spastizin [PER antibody (49)] and
commercial antibodies against spastizin (Atlas HPA035693),
EEA1 (BD Transduction Labs E41120), LAMP1 (Abcam ab24170
and H4A3), CIMPR (2G11; Calbiochem 444105), AP-2 µ2 (AP50;
BD Transduction Labs 611351), LC3 (4E12; MBL M152-3B), LBPA
(Jean Gruenberg), CD63 (H5C6; BD Biosciences), tubulin (DM1A,
Abcam ab7291) and actin (C4, Abcam ab3280). Horse radish per-
oxidase-labelled secondary antibodies were purchased from
Sigma and ﬂuorescently labelled secondary antibodies from
Invitrogen.
Tissue culture and knockdowns
Patient-derived ﬁbroblasts and HeLa M cells were grown in Dul-
becco’s modiﬁed Eagle’s medium (DMEM, Sigma), supplemented
with 10% (v/v) fetal calf serum (Sigma), 2 m -glutamine, 50 U/ml
penicillin and 50 µg/ml streptomycin. Knockdowns in HeLa cells
were performed using the following On-Target Plus SMARTpool
siRNA reagents from Dharmacon, with a non-targeting Smart-
pool siRNA (D-001810-10) used as a control. The siRNAs were:
AP-5 ζ (KIAA0415), L-025284-01 and SPG15: L-031136-01 and
were deconvoluted as in (4). All siRNAs were used at a concentra-
tion of 25 n, and knockdownswere performedwith a double-hit
96 h protocol using Oligofectamine (Invitrogen) and Opti-MEM,
following the manufacturer’s instructions.
Western blotting and tissue preparation
To analyse tissue distribution of AP-5, a mouse or rat was decapi-
tated and tissueswere harvested and homogenizedwith a dounce
homogenizer in lysis buffer (10 m Tris–HCl pH 7.4, 100 mNaCl,
1 m EGTA, 2 m MgCl2, 1% sodium dodecyl sulphate) contain-
ing complete protease inhibitor (Roche) and 10 U/ml Benzonase
(Novagen). Protein concentrations were quantiﬁed with BCA pro-
tein assaykit (Pierce).Western blottingwasperformedasdescribed
previously (49).
In situ hybridization
Two-month-old ratswere killed by decapitation and brains rapid-
ly extracted and ﬁxed in 4% paraformaldehyde for 48 h. Samples
were transferred into phosphate-buffered saline (PBS) containing
30% sucrose for 48 h and then frozen in isopentane (−30°C). The in
situ hybridization was performed on 20 µm coronal cryosections
as described previously (5), using digoxigenin-labelled sense or
antisense riboprobes at a concentration of 100 ng/µl. The RNA
probes covered cDNA positions 15–482 and 1940–2413 of rat
AP5Z1 transcript (accession number NM_001037220.4).
Immunoﬂuorescence and quantiﬁcation
For immunoﬂuorescencemicroscopy, cells were plated into glass-
bottomdishes (MatTek). The cells were then ﬁxedwith 3% formal-
dehyde, permeabilized with PBS/0.1% Triton X-100/0.5% bovine
serum albumin (BSA) or −20°C methanol for 5 min and then
blocked with PBS/0.5% BSA. Cells were labelled as indicated and
imaged with a Zeiss Axiovert 200 inverted microscope using a
Zeiss PlanAchromat 63× oil immersion objective (NA1.4), a Hama-
matsu OCRA-ER2 camera and Improvision Openlab software.
To quantify knockdown phenotypes, we used an automated
ArrayScan VTI microscope (Cellomics/Thermo-Fisher) and the
SpotDetector V4 assay algorithm. Cells were plated onto 96-well
Perkin Elmer microplates, ﬁxed then stained with antibodies
against CD63 or LAMP1, followed by Alexa Fluor 488-donkey
anti-mouse IgG, blue whole-cell stain (Invitrogen) and far red
beads to assist in sample focusing (Flow-Check ﬂuorospheres;
Beckman Coulter). The cells were imaged with a modiﬁed Zeiss
Axiovert 200M inverted microscope, a Zeiss 40×/0.5 Achroplan
objective and a Hamamatsu OCRA-ER camera. More than 1000
cells were quantiﬁed for each condition using ARRAYSCAN
software.
LysoTracker® Red DND-99 (Life Technologies) is a red-ﬂuores-
centdye that ismembrane-permeable andspeciﬁcallyaccumulates
in acidiﬁed compartments. Cells were plated onto glass-bottom
dishes and incubated with 50 n Lysotracker Red and imaged im-
mediately live. Magic Red Cathepsin B substrate (AbD Serotec) is a
membrane-permeable probe which becomes ﬂuorescent upon
cleavage by cathepsin B. Cellswere plated onto glass-bottomdishes
and incubated in CO2-independent media for 45min at 37°C using
Magic Red substrate, according tomanufacturer’s instructions, and
then visualized live.
Conventional EM
Cellswere grown on plastic dishes (ﬁbroblastswere left to recover
in culture for 7 days following trypsinization) and ﬁxed using
double-strength ﬁxative [4% paraformaldehyde (PFA), 5% glu-
taraldehyde, 0.1  cacodylate buffer pH 7.2], added to an equal
volume of culture media. After 2 min, double-strength ﬁx was
replaced by single-strength ﬁx and cells were ﬁxed for 1 h. Cells
were then scraped and pelleted. Cells were then secondarily
ﬁxed with 1% osmium tetroxide and incubated with 1% tannic
acid to enhance contrast. Cells were dehydrated using increasing
percentages of ethanol before being embedded in EPON in beam
capsules. EPON was cured overnight at 65°C.
Ultrathin (50–70 nm) conventional sections were cut using a
diamond knifemounted to a Reichart Ultracut S ultramicrotome.
Sections were collected onto copper grids. Grids were stained
using lead citrate. Sections were viewed on an FEI Tecnai trans-
mission electron microscope (Eindhoven, The Netherlands) at
80 kV.
Thenumber and size of different endocytic structures per unit
area of cytoplasmwere quantiﬁed. For each cell line and respect-
ive age-matched control, complete cell montages from 10 cells
were acquired. Total cytoplasmic volumes were calculated using
ImageJ and the number of organelles scored on the basis of mor-
phology; where endosomes were deﬁned as having an electron
lucent lumen, may contain intraluminal vesicles, but no mem-
brane whorls, and endolysosomes as containing membrane
whorls, may contain intraluminal vesicles and a lucent or dark
lumen and lysosomes having an electron dark lumen and no
membrane whorls or intraluminal vesicles. Organelle sizes were
measured using ImageJ. Means and standard errors are shown.
Cryo-immunoelectron microscopy
For immunogold labelling, ﬁbroblasts were ﬁxed by adding an
equal volume of freshly prepared 4% PFA/0.2% glutaraldehyde
in 0.1  phosphate buffer, pH 7.4. After 2 min, the solution was
removed and cellswere post-ﬁxed in 2% PFA/0.1% glutaraldehyde
in 0.1  phosphate buffer, pH 7.4, for 2 h at room temperature.
Cells were scraped, pelleted and embedded in 12% gelatin at
37◦C and infused with 1.7  sucrose/15% polyvinyl pyrolidone
overnight at 4◦Cbefore beingmounted to stubs in liquid nitrogen.
Ultrathin frozen sections were cut with a diamond knife in a
Reichert Ultracut S ultramicrotome (Leica, Germany), collected
with either 2% methylcellulose: 2.3  sucrose (1:1 ratio) or 2.3 
sucrose alone and mounted on Formvar-coated grids. Ultrathin
sections were labelled with primary antibodies and detected
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using protein-A conjugated to 10 nm colloidal gold (Utrecht
University, The Netherlands). Sections were viewed on an FEI
Tecnai transmission electron microscope (Eindhoven) at 80 kV.
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We thank the patients and their family, without whom this work
would not have been possible. We are grateful to Evan Reid for
helpful discussions and Paul Luzio and Nick Bright for critically
reading this manuscript. We would also like to thank Elodie
Martin, Sylvie Forlani, Tyler Jepperson and Lauren McBeth for
help with aspects of this work and Jean Gruenberg for the anti-
body against LBPA.
Conﬂict of Interest statement. None declared.
Funding
This work was supported by theWellcome Trust (086598; J.H., J.R.
E. and M.S.R.), the European Union (OMICS Call, Neuromics pro-
ject; F.D., A.D., T.E. and G.S.), Verum Foundation (G.S.), Pro-
gramme d’Investissement d’Avenir (ANR-10-IAIHU-06; F.D., A.
D., T.E. and G.S.), ERC starting grant (311149; F.D.), the Intramural
Research Program of the NINDS, National Institutes of Health
(J.C., R.H.R. and C.B.) and National Institutes of Health grant
NS083739 (M.M. andM.C.K.), Doris Duke Foundation (Clinical Sci-
entist Development Award to M.C.K.) and Healthcare Research of
the Italian Ministry of Health (C.M. and C.G.). C.G. also received
partial research support by AriSLA (NOVALS 2010). Funding to
pay the Open Access publication charges for this article was
provided by the Wellcome Trust.
References
1. Owen, D.J., Collins, B.M. and Evans, P.R. (2004) Adaptors for
clathrin coats: structure and function. Annu. Rev. Cell Dev.
Biol., 20, 153–191.
2. Martinelli, D. and Dionisi-Vici, C. (2014) AP1S1 defect causing
MEDNIK syndrome: a new adaptinopathy associated with de-
fective copper metabolism. Annu. NY Acad. Sci., 1314, 55–63.
3. Słabicki, M., Theis, M., Krastev, D.B., Samsonov, S., Mundwil-
ler, E., Junqueira, M., Paszkowski-Rogacz, M., Teyra, J., Henin-
ger, A.K., Poser, I. et al. (2010) A genome-scale DNA repair
RNAi screen identiﬁes SPG48 as a novel gene associated
with hereditary spastic paraplegia. PLoS Biol., 8, e1000408.
4. Hirst, J., Borner, G.H., Edgar, J., Hein,M.Y.,Mann,M., Buchholz,
F., Antrobus, R. and Robinson,M.S. (2013) Interaction between
AP-5 and the hereditary spastic paraplegia proteins SPG11
and SPG15. Mol. Biol. Cell, 24, 2558–2569.
5. Khundadze, M., Kollmann, K., Koch, N., Biskup, C., Nietzsche,
S., Zimmer, G., Hennings, J.C., Huebner, A.K., Symmank, J.,
Jahic, A. et al. (2013) A hereditary spastic paraplegia mouse
model supports a role of ZFYVE26/SPASTIZIN for the endoly-
sosomal system. PLoS Genet., 9, e1003988.
6. Stevanin, G., Santorelli, F.M., Azzedine, H., Coutinho, P., Cho-
milier, J., Denora, P.S., Martin, E., Ouvrard-Hernandez, A.M.,
Tessa, A., Bouslam, N. et al. (2007) Mutations in SPG11, encod-
ing spatacsin, are a major cause of spastic paraplegia with
thin corpus callosum. Nat. Genet., 39, 366–372.
7. Hehr, U., Bauer, P., Winner, B., Schüle, R., Olmez, A., Koehler,
W., Uyanik, G., Engel, A., Lenz, D., Seibel, A. et al. (2007) Long-
term course and mutational spectrum of spatacsin-linked
spastic paraplegia. Annu. Neurol., 62, 656–665.
8. Stevanin, G., Azzedine, H., Denora, P., Boukhris, A., Tazir, M.,
Lossos, A., Rosa, A.L., Lerer, I., Hamri, A., Alegria, P. et al. (2008)
Mutations in SPG11 are frequent in autosomal recessive spas-
tic paraplegia with thin corpus callosum, cognitive decline
and lower motor neuron degeneration. Brain, 131, 772–784.
9. Denora, P.S., Schlesinger, D., Casali, C., Kok, F., Tessa, A.,
Boukhris, A., Azzedine, H., Dotti, M.T., Bruno, C., Truchetto,
J. et al. (2009) Screening of ARHSP-TCC patients expands the
spectrum of SPG11 mutations and includes a large scale
gene deletion. Hum. Mutat., 30, E500–E519.
10. Hanein, S., Martin, E., Boukhris, A., Byrne, P., Goizet, C.,
Hamri, A., Benomar, A., Lossos, A., Denora, P., Fernandez, J.
et al. (2008) Identiﬁcation of the SPG15 gene, encoding spasti-
zin, as a frequent cause of complicated autosomal-recessive
spastic paraplegia, including Kjellin syndrome. Am. J. Hum.
Genet., 82, 992–1002.
11. Schüle, R., Schlipf, N., Synofzik, M., Klebe, S., Klimpe, S., Hehr,
U., Winner, B., Lindig, T., Dotzer, A., Riess, O. et al. (2009) Fre-
quency and phenotype of SPG11 and SPG15 in complicated
hereditary spastic paraplegia. J. Neurol. Neurosurg. Psychiatry,
80, 1402–1404.
12. Pensato, V., Castellotti, B., Gellera, C., Pareyson, D., Ciano, C.,
Nanetti, L., Salsano, E., Piscosquito, G., Sarto, E., Eoli, M. et al.
(2014) Overlapping phenotypes in complex spastic paraple-
gias SPG11, SPG15, SPG35 and SPG48. Brain, 137, 1907–1920.
13. Schlipf, N.A., Schüle, R., Klimpe, S., Karle, K.N., Synofzik, M.,
Wolf, J., Riess, O., Schöls, L. and Bauer, P. (2014) AP5Z1/
SPG48 frequency in autosomal recessive and sporadic spastic
paraplegia. Mol. Genet. Genomic Med., 2, 379–382.
14. Novarino, G., Fenstermaker, A.G., Zaki, M.S., Hofree,M., Silha-
vy, J.L., Heiberg, A.D., Abdellateef, M., Rosti, B., Scott, E., Man-
sour, L. et al. (2014) Exome sequencing links corticospinal
motor neuron disease to common neurodegenerative disor-
ders. Science, 343, 506–511.
15. Finsterer, J., Löscher, W., Quasthoff, S., Wanschitz, J., Auer-
Grumbach, M. and Stevanin, G. (2012) Hereditary spastic
paraplegias with autosomal dominant, recessive, X-linked,
or maternal trait of inheritance. J. Neurol. Sci., 318, 1–18.
16. Tesson, C., Koht, J. and Stevanin, G. (2015) Delving into the
complexity of hereditary spastic paraplegias: how unexpect-
ed phenotypes and inheritance modes are revolutionizing
their nosology. Hum. Genet., 134, 511–538.
17. Goizet, C., Boukhris, A., Maltete, D., Guyant-Maréchal, L., Tru-
chetto, J., Mundwiller, E., Hanein, S., Jonveaux, P., Roelens, F.,
Loureiro, J. et al. (2009) SPG15 is the second most common
cause of hereditary spastic paraplegia with thin corpus callo-
sum. Neurology, 73, 1111–1119.
18. Peden, A.A., Rudge, R.E., Lui, W.W. and Robinson, M.S. (2002)
Assembly and function of AP-3 complexes in cells expressing
mutant subunits. J. Cell Biol., 156, 327–336.
19. Yeung, B.G., Phan, H.L. and Payne, G.S. (1999) Adaptor com-
plex-independent clathrin function in yeast. Mol. Biol. Cell,
10, 3643–3659.
20. Meyer, C., Zizioli, D., Lausmann, S., Eskelinen, E.L., Hamann,
J., Saftig, P., von Figura, K. and Schu, P. (2000) mu1A-adaptin-
deﬁcientmice: lethality, loss of AP-1 binding and rerouting of
mannose 6-phosphate receptors. EMBO J., 19, 2193–2203.
21. Hirst, J., Barlow, L.D., Francisco, G.C., Sahlender, D.A., Sea-
man, M.N., Dacks, J.B. and Robinson, M.S. (2011) The ﬁfth
adaptor protein complex. PLoS Biol., 9, e1001170.
12 | Human Molecular Genetics
 at U
niversity of Cam
bridge on June 25, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
22. Kanagaraj, P., Gautier-Stein, A., Riedel, D., Schomburg, C.,
Cerdà, J., Vollack, N. and Dosch, R. (2014) Soufﬂe/spastizin
controls secretory vesicle maturation during zebraﬁsh oo-
genesis. PLoS Genet., 10, e1004449.
23. Vantaggiato, C., Crimella, C., Airoldi, G., Polishchuk, R., Bona-
to, S., Brighina, E., Scarlato, M., Musumeci, O., Toscano, A.,
Martinuzzi, A. et al. (2013) Defective autophagy in spastizin
mutated patients with hereditary spastic paraparesis type
15. Brain, 136, 3119–3139.
24. Sagona, A.P., Nezis, I.P., Bache, K.G., Haglund, K., Bakken, A.C.,
Skotheim, R.I. and Stenmark, H. (2011) A tumor-associated
mutation of FYVE-CENT prevents its interaction with Beclin
1 and interferes with cytokinesis. PLoS ONE, 6, e17086.
25. Chang, J., Lee, S. and Blackstone, C. (2014) Spastic paraplegia
proteins spastizin and spatacsin mediate autophagic lyso-
some reformation. J. Clin. Invest., 124, 5249–5262.
26. Renvoisé, B., Chang, J., Singh, R., Yonekawa, S., FitzGibbon, E.
J., Mankodi, A., Vanderver, A., Schindler, A., Toro, C., Gahl, W.
A. et al. (2014) Lysosomal abnormalities in hereditary spastic
paraplegia types SPG15 and SPG11. Annu. Clin. Transl. Neurol.,
1, 379–389.
27. Mullock, B.M., Bright, N.A., Fearon, C.W., Gray, S.R. and Luzio,
J.P. (1998) Fusion of lysosomeswith late endosomes produces
a hybrid organelle of intermediate density and is NSF de-
pendent. J. Cell Biol., 140, 591–601.
28. Bright, N.A., Gratian, M.J. and Luzio, J.P. (2005) Endocytic
delivery to lysosomes mediated by concurrent fusion and
kissing events in living cells. Curr. Biol., 15, 360–365.
29. Huotari, J. and Helenius, A. (2011) Endosome maturation.
EMBO J., 30, 3481–3500.
30. Luzio, J.P., Pryor, P.R. and Bright, N.A. (2007) Lysosomes:
fusion and function. Nat. Rev. Mol. Cell Biol., 8, 622–632.
31. Pols, M.S. and Klumperman, J. (2009) Trafﬁcking and function
of the tetraspanin CD63. Exp. Cell Res., 315, 1584–1592.
32. Kobayashi, T., Stang, E., Fang, K.S., deMoerloose, P., Parton, R.
G. and Gruenberg, J. (1998) A lipid associated with the anti-
phospholipid syndrome regulates endosome structure and
function. Nature, 392, 193–197.
33. Martin, E., Yanicostas, C., Rastetter, A., Naini, S.M.,
Maouedj, A., Kabashi, E., Rivaud-Péchoux, S., Brice, A., Ste-
vanin, G. and Soussi-Yanicostas, N. (2012) Spatacsin and
spastizin act in the same pathway required for proper
spinalmotor neuron axon outgrowth in zebraﬁsh.Neurobiol.
Dis., 48, 299–308.
34. Parkinson-Lawrence, E.J., Shandala, T., Prodoehl, M., Plew, R.,
Borlace, G.N. and Brooks, D.A. (2010) Lysosomal storage dis-
ease: revealing lysosomal function and physiology. Physi-
ology, 25, 102–115.
35. Vergarajauregui, S., Martina, J.A. and Puertollano, R. (2011)
LAPTMs regulate lysosomal function and interact with
mucolipin 1: new clues for understanding mucolipidosis
type IV. J. Cell Sci., 124, 459–468.
36. Walkley, S.U. (1998) Cellular pathology of lysosomal storage
disorders. Brain Pathol., 8, 175–193.
37. Ikeda, K., Goebel, H.H., Burck, U. and Kohlschütter, A. (1982)
Ultrastructural pathology of human lymphocytes in lyso-
somal disorders: a contribution to their morphological diag-
nosis. Eur. J. Pediatr., 138, 179–185.
38. Lieberman, A.P., Puertollano, R., Raben, N., Slaugenhaupt, S.,
Walkley, S.U. and Ballabio, A. (2012) Autophagy in lysosomal
storage disorders. Autophagy, 8, 719–730.
39. Vitner, E.B., Platt, F.M. and Futerman, A.H. (2010) Common
and uncommon pathogenic cascades in lysosomal storage
diseases. J. Biol. Chem., 285, 20423–20427.
40. Cox, T.M. and Cachón-González, M.B. (2012) The cellular
pathology of lysosomal diseases. J. Pathol., 226, 241–254.
41. Saftig, P. and Klumperman, J. (2009) Lysosome biogenesis and
lysosomal membrane proteins: trafﬁcking meets function.
Nat. Rev. Mol. Cell Biol., 10, 623–635.
42. Platt, F.M., Boland, B. and van der Spoel, A.C. (2012) The cell
biology of disease: lysosomal storage disorders: the cellular
impact of lysosomal dysfunction. J. Cell Biol., 199, 723–734.
43. Müller vom Hagen, J., Karle, K.N., Schüle, R., Krägeloh-Mann,
I. and Schöls, L. (2014) Leukodystrophies underlying cryptic
spastic paraparesis: frequency and phenotype in 76 patients.
Eur. J. Neurol., 21, 983–988.
44. Walkley, S.U. andVanier,M.T. (2009) Secondary lipid accumula-
tion in lysosomal disease. Biochim. Biophys. Acta, 1793, 726–736.
45. Pols, M.S., vanMeel, E., Oorschot, V., ten Brink, C., Fukuda, M.,
Swetha, M.G., Mayor, S. and Klumperman, J. (2013) hVps41
and VAMP7 function in direct TGN to late endosome trans-
port of lysosomal membrane proteins. Nat. Commun., 4, 1361.
46. Miller, A., Schafer, J., Upchurch, C., Spooner, E., Huynh, J., Her-
nandez, S.,McLaughlin, B., Oden, L. and Fares, H. (2015)Muco-
lipidosis type IV protein TRPML1-dependent lysosome
formation. Trafﬁc, 16, 284–297.
47. Goldman, S.D. and Krise, J.P. (2010) Niemann–Pick C1 func-
tions independently of Niemann–Pick C2 in the initial stage
of retrograde transport of membrane-impermeable lyso-
somal cargo. J. Biol. Chem., 285, 4983–4994.
48. Mallaret, M., Lagha-Boukbiza, O., Biskup, S., Namer, I.J., Ru-
dolf, G., Anheim, M. and Tranchant, C. (2014) SPG15: a cause
of juvenile atypical levodopa responsive parkinsonism.
J. Neurol., 261, 435–437.
49. Murmu, R.P., Martin, E., Rastetter, A., Esteves, T., Muriel, M.P.,
El Hachimi, K.H., Denora, P.S., Dauphin, A., Fernandez, J.C.,
Duyckaerts, C. et al. (2011) Cellular distribution and subcellu-
lar localization of spatacsin and spastizin, two proteins in-
volved in hereditary spastic paraplegia. Mol. Cell Neurosci.,
47, 191–202.
Human Molecular Genetics | 13
 at U
niversity of Cam
bridge on June 25, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
